Aradigm Corporation And Canadian Department Of National Defence Extend AERx Liposomal Ciprofloxacin Development Program

Aradigm Corporation (NASDAQ: ARDM) today announced that Defence R&D Canada (DRDC) has extended the development program for the aerosolized delivery of liposome-encapsulated ciprofloxacin as a treatment for bioterror-related anthrax.

MORE ON THIS TOPIC